Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infection prevention and control risk assessment and policy for respiratory viral infections in National Health Service trusts in England: a national survey.

The Journal of hospital infection·2026
Same author

Evaluation of SARS-CoV-2 lateral flow device sensitivity: a comparison of systematic laboratory assessments with manufacturer-reported sensitivity.

EClinicalMedicine·2025
Same author

Emerging <i>Clostridioides difficile</i> strains belonging to PCR ribotype 955 in Serbia are distinct from metronidazole-resistant RT955 outbreak isolates from the UK.

Emerging microbes & infections·2025
Same author

Urinary tract infection in adults: gaps in current guidelines - opinions from an international multidisciplinary panel and relevance to clinical practice.

BMC proceedings·2025
Same author

Correction: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England.

Applied health economics and health policy·2025
Same author

Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England.

Applied health economics and health policy·2024
Same journal

Assessment of the enhanced antibacterial activity of snail mucus, thymol, and ferulic acid in a rat model of burn wounds infected with <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i>.

Future microbiology·2026
Same journal

Mechanistic insights into the inhibition of biofilm formation and antibacterial action of endophytic <i>Streptomyces</i> strain KJ7TB2 isolated from the Indian Sundarbans Mangrove estuary.

Future microbiology·2026
Same journal

Applications of lupeol to manage fungal infections: a promising multi-target molecule.

Future microbiology·2026
Same journal

Benzyl isothiocyanate-loaded chitosan beads: a novel strategy to combat biofilm formation by <i>Staphylococcus aureus</i> and <i>Escherichia coli</i>.

Future microbiology·2026
Same journal

<i>Mycobacterium colombiense</i> isolation among people living with human immunodeficiency virus: a case series.

Future microbiology·2026
Same journal

Thwarting the biothreat in the 21st century: means and methods.

Future microbiology·2026
See all related articles

Related Experiment Video

Updated: Dec 31, 2025

Author Spotlight: Unlocking New Insights in fNIRS Studies - A Novel Framework for Inter-Brain Synchrony Analysis
05:59

Author Spotlight: Unlocking New Insights in fNIRS Studies - A Novel Framework for Inter-Brain Synchrony Analysis

Published on: October 6, 2023

3.1K

Interview with Professor Mark Wilcox.

Mark Wilcox1,2

  • 1Leeds Teaching Hospitals NHS Trust, Department of Microbiology, Old Medical School, LGI, Leeds, LS1 3EX.

Future Microbiology
|August 6, 2016
PubMed
Summary
This summary is machine-generated.

Professor Mark Wilcox is a leading expert in Clostridium difficile infection and antimicrobial resistance. His extensive research and clinical work focus on infection prevention and the development of novel antimicrobial agents.

Keywords:
C. difficileCDIcomorbiditiesrecurrence

More Related Videos

Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer
08:20

Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer

Published on: May 21, 2019

5.9K
Optical Screening of Novel Bacteria-specific Probes on Ex Vivo Human Lung Tissue by Confocal Laser Endomicroscopy
09:24

Optical Screening of Novel Bacteria-specific Probes on Ex Vivo Human Lung Tissue by Confocal Laser Endomicroscopy

Published on: November 29, 2017

7.9K

Related Experiment Videos

Last Updated: Dec 31, 2025

Author Spotlight: Unlocking New Insights in fNIRS Studies - A Novel Framework for Inter-Brain Synchrony Analysis
05:59

Author Spotlight: Unlocking New Insights in fNIRS Studies - A Novel Framework for Inter-Brain Synchrony Analysis

Published on: October 6, 2023

3.1K
Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer
08:20

Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer

Published on: May 21, 2019

5.9K
Optical Screening of Novel Bacteria-specific Probes on Ex Vivo Human Lung Tissue by Confocal Laser Endomicroscopy
09:24

Optical Screening of Novel Bacteria-specific Probes on Ex Vivo Human Lung Tissue by Confocal Laser Endomicroscopy

Published on: November 29, 2017

7.9K

Area of Science:

  • Medical Microbiology
  • Infection Prevention and Control
  • Antimicrobial Resistance

Background:

  • Professor Mark Wilcox holds key leadership positions in microbiology and infection control at Leeds Teaching Hospitals and the University of Leeds.
  • He has extensive experience in infection prevention, serving as Director of Infection Prevention and Clinical Director of Pathology.
  • His expertise includes Clostridium difficile infection and the UK C. difficile Reference Laboratory.

Discussion:

  • Professor Wilcox chairs Public Health England's Rapid Review Panel, evaluating infection prevention products for the NHS.
  • He is actively involved in national and international working groups focused on Clostridium difficile infection.
  • He provides clinical advice for the regulatory approval of new antimicrobial agents by the FDA and EMA.

Key Insights:

  • Leads a multidisciplinary research team focused on healthcare-associated infections, diagnostics, and antimicrobial resistance.
  • His team's projects encompass various aspects of Clostridium difficile infection and the clinical development of new antimicrobials.
  • Author of over 400 publications and co-editor of "Antimicrobial Chemotherapy".

Outlook:

  • Continued research into C. difficile infection and antimicrobial resistance.
  • Contribution to the development and approval of novel antimicrobial therapies.
  • Advancing infection prevention strategies within healthcare settings.